Sensus Healthcare shares surge 19.19% intraday as CMS new standard boosts SRT reimbursement rates by 300% and skin cancer demand rises.

Sensus Healthcare surged 19.19% intraday, driven by two key factors: the 2026 CMS new standard implementation, which recognizes its Superficial Radiation Therapy (SRT) technology as an independent treatment method with exclusive codes boosting reimbursements by over 300%, and rising U.S. skin cancer rates (1 in 5 Americans expected to develop skin cancer), increasing demand for its non-invasive SRT treatments that achieve over 99% recurrence prevention rates.